Kailera Therapeutics, Inc. (KLRA) vs Rapport Therapeutics, Inc. Common Stock (RAPP)

A side-by-side comparison of Kailera Therapeutics, Inc. and Rapport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Kailera Therapeutics, Inc. logo
KLRA
Kailera Therapeutics, Inc.
$1.40B
$10.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Rapport Therapeutics, Inc. Common Stock logo
RAPP
Rapport Therapeutics, Inc. Common Stock
$1.49B
$31.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — KLRA vs RAPP

growth of $100 · dividends reinvested · last 1y
KLRA -58.3% (-58.3%/yr)RAPP -18.9% (-18.9%/yr)RAPP compounded faster over this window
406080100120Start $100$42$81
KLRA RAPP

KLRA vs RAPP: by the numbers

  • •RAPP is the larger company ($1.49B vs $1.40B market cap).
  • •Both run net losses; KLRA's is the smaller (0.00% vs -685.80% net margin).

Metrics side by side

Valuation

MetricKLRARAPP
P/S ratioN/A74.49
P/B ratio1.253.52

Profitability

MetricKLRARAPP
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%-685.80%
ROEN/A-32.43%
ROIC-24.52%-35.66%

Go deeper

Full KLRA analysisFull RAPP analysisInteractive comparison tool

Dig into the metrics

Kailera Therapeutics ROERapport Therapeutics, Inc. Common Stock ROEKailera Therapeutics operating marginRapport Therapeutics, Inc. Common Stock operating marginKailera Therapeutics revenue growthRapport Therapeutics, Inc. Common Stock revenue growthKailera Therapeutics free cash flowRapport Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.